Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down Following Analyst Downgrade

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) gapped down before the market opened on Thursday after Chardan Capital lowered their price target on the stock from $16.00 to $14.00. The stock had previously closed at $4.09, but opened at $3.51. Chardan Capital currently has a buy rating on the stock. Iovance Biotherapeutics shares last traded at $3.6430, with a volume of 14,841,725 shares traded.

Several other equities research analysts have also issued reports on IOVA. Wall Street Zen upgraded shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. The Goldman Sachs Group reissued a “sell” rating and set a $2.00 price objective on shares of Iovance Biotherapeutics in a research report on Thursday, February 5th. Citizens Jmp upgraded Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 price target on the stock in a report on Tuesday, March 3rd. Barclays raised their target price on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Finally, UBS Group lifted their price target on shares of Iovance Biotherapeutics from $2.00 to $4.00 and gave the company a “neutral” rating in a research note on Thursday, March 5th. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $8.63.

Iovance Biotherapeutics News Roundup

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reaffirmed or raised confidence in its longer-term growth story by outlining 2026 revenue guidance of $350 million to $370 million and Q2 revenue guidance of $86 million to $88 million, which suggests management still expects solid commercial momentum. Article: Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
• Positive Sentiment: A Chardan Capital analyst kept a Buy rating on Iovance even after trimming the price target to $14 from $16, indicating Wall Street still sees substantial upside from current levels. Article: Iovance Biotherapeutics had its price target lowered by Chardan Capital
• Neutral Sentiment: The company’s Q1 loss of $0.19 per share matched expectations, and revenue grew 44.9% year over year, showing progress even though the quarter was not enough to satisfy investors. Article: Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates
• Negative Sentiment: Revenue came in below analyst forecasts at $71.43 million versus $77.84 million expected, with weaker-than-expected product sales weighing on sentiment and triggering the stock’s decline. Article: IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Institutional Trading of Iovance Biotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Invenomic Capital Management LP lifted its holdings in Iovance Biotherapeutics by 27.1% during the 3rd quarter. Invenomic Capital Management LP now owns 10,541,608 shares of the biotechnology company’s stock worth $22,875,000 after buying an additional 2,246,945 shares in the last quarter. Mirador Capital Partners LP boosted its stake in shares of Iovance Biotherapeutics by 100.9% in the 4th quarter. Mirador Capital Partners LP now owns 1,034,544 shares of the biotechnology company’s stock valued at $2,824,000 after purchasing an additional 519,519 shares in the last quarter. Aberdeen Group plc increased its stake in shares of Iovance Biotherapeutics by 25.1% in the fourth quarter. Aberdeen Group plc now owns 759,522 shares of the biotechnology company’s stock valued at $2,073,000 after buying an additional 152,312 shares during the period. Rhenman & Partners Asset Management AB increased its stake in Iovance Biotherapeutics by 69.5% in the third quarter. Rhenman & Partners Asset Management AB now owns 1,097,827 shares of the biotechnology company’s stock valued at $2,382,000 after purchasing an additional 450,000 shares in the last quarter. Finally, Rafferty Asset Management LLC boosted its holdings in Iovance Biotherapeutics by 65.1% during the 3rd quarter. Rafferty Asset Management LLC now owns 482,975 shares of the biotechnology company’s stock worth $1,048,000 after acquiring an additional 190,522 shares during the last quarter. Institutional investors and hedge funds own 77.03% of the company’s stock.

Iovance Biotherapeutics Price Performance

The stock has a market capitalization of $1.62 billion, a P/E ratio of -3.81 and a beta of 0.69. The company has a 50 day simple moving average of $3.81 and a 200-day simple moving average of $2.94.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.19). Iovance Biotherapeutics had a negative net margin of 123.92% and a negative return on equity of 50.57%. The business had revenue of $71.43 million for the quarter, compared to the consensus estimate of $77.84 million. During the same period in the previous year, the firm earned ($0.36) EPS. The company’s quarterly revenue was up 44.9% compared to the same quarter last year. As a group, equities analysts forecast that Iovance Biotherapeutics, Inc. will post -0.61 earnings per share for the current fiscal year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.